2. Disease Areas
  3. Neurological, Eye or Ear Disease
  4. Visual System Disease
  5. Dry Eye Disease

Dry Eye Disease

Dry Eye Disease is a multifactorial disorder characterized by tear film instability and ocular surface damage due to either inadequate tear production or excessive evaporation, primarily driven by Meibomian gland dysfunction. It predominantly affects older adults (≥50 years), with higher prevalence in women, and shows seasonal variation with increased incidence in spring. Environmental factors such as high temperature, air pollutants (e.g., carbon monoxide, nitrogen dioxide), and living in industrial areas contribute to disease development. Pathophysiology involves tear film osmolarity imbalance, immune cell infiltration, ocular surface inflammation, and altered lipid composition in tears, including increased saturated long-chain fatty acids, reduced unsaturated fatty acids, and abnormal levels of specific lipid classes such as wax esters, diesters, OAHFAs, cholesterol esters, and triglycerides. These changes reflect disrupted lipid layer function and are associated with the clinical manifestations of dry eye.

References:

Dry Eye Disease (9):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-132596A
    Tivanisiran sodium 1848239-71-3
    Tivanisiran sodium (SYL1001 sodium) is a small interfering RNA (siRNA) targeting TRPV1 . Tivanisiran sodium induces the degradation of TRPV1 mRNA, thereby inhibiting protein synthesis. Tivanisiran sodium alleviates ocular discomfort and pain, and improves ocular hyperemia and tear quality. Tivanisiran sodium is applicable to research related to dry eye disease.
    Tivanisiran sodium
  • HY-172435
    Rezuforimod 1431754-15-2 98.63%
    Rezuforimod (AGN-232411; AG-80308) is an ophthalmic solution targeting the formyl peptide receptor (FPR) pathway. Rezuforimod exerts anti-inflammatory effects by targeting the formyl peptide receptor pathway. Administered topically, Rezuforimod significantly reduces the corneal conjunctival staining score and improves ocular discomfort symptoms, with no serious adverse events reported and favorable overall safety profile. Rezuforimod shows remarkable potential to serve as a novel therapeutic option for dry eye disease.
    Rezuforimod
  • HY-B0633O
    Hyaluronic acid sodium (MW 5000) 9067-32-7
    Hyaluronic acid (sodium) (MW 5000) is a biopolymer composed of repeating disaccharide units with a molecular weight of 5000. Hyaluronic acid (sodium) (MW 5000) can be used for dry-eye syndrome research.
    Hyaluronic acid sodium (MW 5000)
  • HY-171333
    TMEM16A modulator-1 2367645-32-5
    TMEM16A modulator-1 (compound 36) is a positive modulator of the calcium-activated chloride channel (CaCC) TMEM16A. TMEM16A modulator-1 can be used for TMEM16A-related diseases research, particularly respiratory diseases and conditions.
    TMEM16A modulator-1
  • HY-171216
    GW559090 278598-52-0
    GW559090 is a selective, competitive, and high-affinity α4 integrin antagonist with a Kd of 0.19 nM for α4β1. GW559090 can effectively block the binding of α4β1 to vascular cell adhesion molecule 1 (VCAM-1) and fibronectin with IC50 values of 7.72 and 8.04 nM. GW559090 also inhibits the interaction between α4β7 and mucosal addressin cell adhesion molecule 1 (MAdCAM-1) (IC50 = 23 nM). GW559090 can inhibit inflammatory infiltration in the eyes, repair the corneal barrier and restore the function of goblet cells. GW559090 can be used for research of Sjögren's syndrome associated dry eye.
    GW559090
  • HY-125500
    TOP1362 1630203-25-6
    TOP1362 is a narrow spectrum kinase inhibitor. TOP1362 is a potent inhibitor of P38-α and Syk kinases with Kd values of 26 and 18 nM, respectively and an IC50 of 14 nM in the Src kinase activity assay. TOP1362 potently inhibits P38-α, Src and Syk. TOP1362 can be used in the research of dry eye syndrome.
    TOP1362
  • HY-180939
    LFA-1-IN-2
    LFA-1-IN-2 (Compound 25) is a potent LFA-1 inhibitor with a Kd of 21.46 μM. LFA-1-IN-2 inhibits ICAM-1-mediated cell adhesion. LFA-1-IN-2 protects cells from inflammatory hyperosmotic stress. LFA-1-IN-2 improves dry eye disease.
    LFA-1-IN-2
  • HY-151611A
    UAMC-00050 free base 934622-26-1
    UAMC-00050 free base is a potent trypsin-like serine protease inhibitor. UAMC-00050 free base can be used in research of dry eye syndrome and ocular inflammation.
    UAMC-00050 free base
  • HY-183905
    KR-67607 1401564-00-8
    KR-67607 is a selective 11β-HSD1 inhibitor, with an IC50 value of 4.8 nM against h11β-HSD1 and 7.1 nM against mouse 11β-HSD1. KR-67607 inhibits stress-induced Glucocorticoid receptor nuclear translocation, reduces cortisol levels, suppresses the expression of ROS and proinflammatory cytokines, and enhances Nrf-2-mediated antioxidant gene transcription. KR-67607 maintains trabecular meshwork structure and reverses elevated intraocular pressure. KR-67607 improves ocular antioxidant activity and mucus secretion, reverses ocular surface damage, and prevents ischemia-reperfusion induced ocular injury. KR-67607 can be used in research related to glaucoma and dry eye disease.
    KR-67607